111 Capital Takes $3.71 Million Position in Pfizer Inc. $PFE

Key Points

• 111 Capital acquired 153,909 Pfizer shares worth approximately $3.71 million, making Pfizer its 28th-largest holding and representing about 0.6% of its portfolio.
• Pfizer exceeded quarterly expectations with $0.77 EPS versus a $0.68 consensus estimate and $15.03 billion in revenue. The company declared a quarterly dividend of $0.43 per share, equivalent to a 6.3% annualized yield.
• Analysts maintain a consensus “Hold” rating with a $28.28 price target, while patent-expiration concerns remain a key risk despite potential longer-term opportunities in Lyme disease, obesity and oncology treatments.

111 Capital bought a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 153,909 shares of the biopharmaceutical company's stock, valued at approximately $3,706,000. Pfizer accounts for about 0.6% of 111 Capital's investment portfolio, making the stock its 28th largest position.

Several other hedge funds have also recently modified their holdings of PFE. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at $26,000. Keb Asset Management LLC purchased a new stake in shares of Pfizer during the second quarter valued at about $26,000. HFM Investment Advisors LLC lifted its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 427 shares during the last quarter. Evolution Wealth Management Inc. boosted its stake in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 566 shares in the last quarter. Finally, Abound Financial LLC purchased a new position in Pfizer in the fourth quarter worth $31,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 1.6%

PFE stock opened at $27.30 on Wednesday. The firm's fifty day simple moving average is $25.18 and its 200-day simple moving average is $26.21. The company has a market capitalization of $155.57 billion, a P/E ratio of 35.91 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm's revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.3%. The ex-dividend date is Friday, July 24th. Pfizer's dividend payout ratio (DPR) is currently 226.32%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PFE. Citigroup increased their price objective on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 29th. Cantor Fitzgerald restated a "neutral" rating and set a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. Wolfe Research restated an "underperform" rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Guggenheim lowered their target price on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research note on Friday, August 7th. Finally, HSBC downgraded shares of Pfizer from a "buy" rating to a "hold" rating and dropped their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer has an average rating of "Hold" and a consensus target price of $28.28.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: EMA validates Lyme vaccine filing: The European Medicines Agency validated Pfizer and Valneva’s marketing application for their Lyme disease vaccine candidate, allowing the application to proceed to a full regulatory review. The filing follows late-stage data showing encouraging efficacy and safety. Approval could create a new commercial opportunity for Pfizer, although regulatory and launch risks remain. Pfizer Gets EMA Lyme Vaccine Filing Validation
• Positive Sentiment: Pipeline and intellectual-property support: Pfizer completed a Phase 1 study of its early-stage obesity candidate PF-08653944, maintaining optionality in a high-growth therapeutic market. A separate patent analysis also identified Pfizer as a leading holder of next-generation antibody-drug-conjugate patents, strengthening the company’s potential position in cancer treatment. Both developments are longer-term catalysts rather than immediate revenue drivers. Pfizer Advances Early Obesity Drug PF-08653944
• Neutral Sentiment: Healthcare-sector momentum: Healthcare indexes rose broadly late Tuesday, providing a favorable trading backdrop for defensive, dividend-paying pharmaceutical companies such as Pfizer. The sector move appears to be a market-wide factor rather than a Pfizer-specific fundamental change. Healthcare Stocks Climb Late Afternoon
• Neutral Sentiment: Obesity-drug competition and deal interest: Kailera Therapeutics’ large obesity-drug IPO highlights intense industry interest in the market and could increase attention on Pfizer’s pipeline or potential acquisition opportunities. At the same time, rising competition makes Pfizer’s early-stage program more speculative. Kailera Therapeutics Obesity IPO
• Negative Sentiment: Patent-cliff concerns remain: Despite Pfizer’s low valuation and attractive dividend, analysts continue to warn that upcoming patent expirations could pressure revenue and earnings as key products face generic or biosimilar competition. This remains the primary fundamental overhang on PFE. Pfizer Still Cheap Valuation Meets a Looming Patent Cliff

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source